New thoughts on the pathobiology of regimen-related mucosal injury

被引：26
|
作者：
Anthony, Lowell
Bowen, Joanne
Garden, Adam
Hewson, Ian
Sonis, Stephen
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
[3] LSUHSC, Stanley S Scott Canc Ctr, New Orleans, LA USA
[4] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia
[5] Royal Adelaide Hosp, Dept Med Oncol, Adelaide, SA 5000, Australia
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
SUPPORTIVE CARE IN CANCER | 2006年 / 14卷 / 06期
关键词：
mucosal injury; cancer theraphy; radiation; drugs; genetic influences;
D O I：
10.1007/s00520-006-0058-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Our understanding of the biological basis for mucosal barrier injury (mucositis) induced by cancer therapy with radiation or drugs continues to evolve. A patient's mucosal response to cancer therapy appears to be controlled by both global (i.e. gender, underlying systemic disease, race) and tissue specific (i.e. epithelial type, intrinsic endocrine system, local microbial environment, function) factors. Conclusion: Interactions of these elements, coupled with underlying genetic influences, most likely govern the risk, course and severity of regimen-related mucosal injury.
引用
收藏
页码：516 / 518
页数：3
相关论文
共 50 条
  • [1] New thoughts on the pathobiology of regimen-related mucosal injury
    Lowell Anthony
    Joanne Bowen
    Adam Garden
    Ian Hewson
    Stephen Sonis
    [J]. Supportive Care in Cancer, 2006, 14 : 516 - 518
  • [2] New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
    Cinausero, Marika
    Aprile, Giuseppe
    Ermacora, Paola
    Basile, Debora
    Vitale, Maria G.
    Fanotto, Valentina
    Parisi, Giuseppe
    Calvetti, Lorenzo
    Sonis, Stephen T.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [3] Biomarkers of regimen-related mucosal injury
    Gibson, Rachel J.
    Bowen, Joanne M.
    [J]. CANCER TREATMENT REVIEWS, 2011, 37 (06) : 487 - 493
  • [4] Prevention and treatment of regimen-related mucosal toxicity
    Bowen, Joanne M.
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2008, 3 (02) : 68 - 75
  • [5] Regimen-Related Mucosal Injury of the Gut Increased the Incidence of CMV Disease after Allogeneic Bone Marrow Transplantation
    Shigematsu, Akio
    Yasumoto, Atsushi
    Yamamoto, Satoshi
    Sugita, Junichi
    Kondo, Takeshi
    Onozawa, Masahiro
    Kahata, Kaoru
    Endo, Tomoyuki
    Ota, Shuichi
    Sato, Norihiro
    Takahata, Mutsumi
    Okada, Kohei
    Tanaka, Junji
    Hashino, Satoshi
    Nishio, Mitsufumi
    Koike, Takao
    Asaka, Masahiro
    Imamura, Masahiro
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (06) : 679 - 685
  • [6] Effect of busulphan dose adjustment on regimen-related toxicity
    Hassan, Z.
    Remberger, M.
    Ringden, O.
    Oberg, G.
    Bekassy, A.
    Hassan, M.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S48 - S48
  • [7] BlinatumomabDeath due to regimen-related toxicity: case report
    [J]. Reactions Weekly, 2019, 1740 (1) : 68 - 68
  • [8] Pharmacotherapy for the management of cancer regimen-related oral mucositis
    Villa, Alessandro
    Sonis, Stephen T.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) : 1801 - 1807
  • [9] Effect of busulphan dose adjustment on regimen-related toxicity.
    Hassan, Zuzana
    Remberger, Mats
    Ringden, Olle
    Oberg, Gunnar
    Bekassy, Albert N.
    Hassan, Moustapha
    [J]. BLOOD, 2006, 108 (11) : 97A - 97A
  • [10] Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities
    Mancini, Maria L.
    Sonis, Stephen T.
    [J]. FRONTIERS IN PHARMACOLOGY, 2014, 5
12345